GIM
EW icon

Glenmede Investment Management’s Edwards Lifesciences EW Stock Holding History

Glenmede Investment Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$14.2M Sell
182,172
-13,499
-7% -$1.05M 0.07% 260
2025
Q2 		$15.3M Buy
+195,671
New +$14.6M 0.08% 244

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Glenmede Investment Management's EW Position: Q3 2025 in Review

Glenmede Investment Management reduced its Edwards Lifesciences (EW) stake by 6.9% in Q3 2025, selling an estimated $1.05M and leaving 182,172 shares worth $14.2M. The position accounts for 0.07% of the portfolio, ranked #260.

Glenmede Investment Management first reported a position in EW in Q2 2025 and has held it in 2 quarters since. The position peaked at $15.3M in Q2 2025. 1,253 funds tracked by Wall St. Rank hold EW as of Q3 2025.

  • Glenmede Investment Management held 182,172 shares of Edwards Lifesciences worth $14.2M as of Q3 2025.
  • Glenmede Investment Management sold 13,499 Edwards Lifesciences shares in Q3 2025, an estimated $1.05M.
  • Edwards Lifesciences made up 0.07% of Glenmede Investment Management's portfolio in Q3 2025, its #260 holding.
  • Glenmede Investment Management first reported a position in Edwards Lifesciences in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Edwards Lifesciences position peaked at $15.3M in Q2 2025.
  • 1,253 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.